

EFSD

European Foundation for the Study of Diabetes

Report - 2010

CONTENTS	PAGE
Introduction	
 <u>Grant Programmes 2010:</u>	
EFSD Clinical Research Grants in the Field of Diabetes	6
EFSD New Horizons Collaborative Research Initiative	7
EFSD Research Programme in Diabetes and Cancer	8
EFSD/Amylin Paul Langerhans Grants on Interaction between the Brain, Gut, Liver and Periphery and its Importance in Diabetes	9
EFSD/Chinese Diabetes Society/Lilly Collaborative Diabetes Research Programme	10
EFSD/D-Cure Young Investigator Awards for Collaborative Diabetes Research between Israel and Europe	11
EFSD/GlaxoSmithKline Programme in Immunomodulation and/or Modulation of the Incretin Pathway in Type 1 and Type 2 Diabetes	12
EFSD/JDRF/Novo Nordisk European Programme in Type 1 Diabetes Research	13
EFSD/Lilly European Diabetes Research Programme	15
EFSD/Merck Sharp & Dohme (MSD) European Basic Research Programme on Beta Cell Function and Survival	16
EFSD/Merck Sharp & Dohme (MSD) European Clinical Research Programme on Incretins, Gut Physiology and Pancreatic Islets in Type 2 Diabetes	17
EFSD/Novo Nordisk Partnership for Diabetes Research in Europe	18
EFSD/Pfizer European Programme for Research into Cardiovascular Risk Reduction in Patients with Diabetes	19

EFSD/sanofi-aventis European Research Programme in Micro- and Macrovascular Complications Of Diabetes	20
--	----

Fellowships 2010:

EFSD Albert Renold Travel Fellowships supported by Merck Sharp & Dohme (MSD)	22
---	----

EFSD/Chinese Diabetes Society/Lilly Research Fellowships	23
--	----

EFSD/Lilly Research Fellowships	24
---	----

New Programmes 2011:

EFSD European Diabetes Research Programme in Patient Education supported by an educational research grant from AstraZeneca/BMS	26
--	----

EFSD/Janssen Programme for the Study of the Role of the Kidney in Diabetes	27
--	----

EFSD/MSD Fellowships for Research on the Endocrine Pancreas	28
---	----

*Note: the above relates solely to programmes which have been officially agreed
at the time of writing this Report.*

EFSD Review Committee Members	29
--------------------------------------	----

EFSD Executive Committee and Administration	30
--	----

In 1999 the European Association for the Study of Diabetes (EASD) created its own Foundation - the European Foundation for the Study of Diabetes (EFSD) - in order to support more actively diabetes research in Europe and to serve even more effectively the goals of EASD, which are: to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge, and to facilitate its application.

EFSD is a non-profit foundation, which seeks to support the highest quality research in Europe to find a cure for all types of diabetes and associated complications and to prevent their onset. EFSD aims to co-operate with other government and non-government agencies in order to increase funding in European diabetes research as a means of achieving its goals. Through its various activities and programmes, the Foundation also strives to enhance awareness in Europe of the severity and magnitude of this devastating disease. It is the ambition of the Executive Committee to develop EFSD as the main European funding agency for diabetes research.

The Foundation is closely related to EASD; it is governed exclusively by the Executive Committee of EASD, which itself is under the close supervision of the EASD Council and General Assembly. The Foundation operates on a strictly non-profit basis under the control of the relevant authorities in Germany.

[EFSD and its partners bring over Euro 74 Million to European diabetes research](#)

In order to foster diabetes research at the highest level in Europe, EFSD has entered into innovative partnerships with other foundations and with industry. Through such partnerships, as well as its own stand-alone funding initiatives, to date EFSD has committed over **Euro 74 Million** to diabetes research in Europe.

Further information on EFSD Award Programmes is available on the website of the Foundation: www.EuropeanDiabetesFoundation.org. An RFA (request for applications) for each Programme is printed in *Diabetologia* (the official journal of EASD), and announced in the monthly e-mail sent to EASD members.

All applications are subject to rigorous peer review by a fully independent panel of leading experts in the field, and awards are based on scientific merit. Applications from non-profit organisations are welcome from Europe or any associated country as well as named non-European countries in the context of collaborative research programmes.

GRANT

PROGRAMMES

2010

Clinical Research Grants in the Field of Diabetes

Plan

The EFSD Clinical Research Grants Programme was created to stimulate research into all aspects of diabetes, but with particular reference to epidemiology/genetics of prediabetes, diabetes and its micro- and macrovascular complications, pathophysiology and clinical aspects including vascular physiology and obesity. The proposed investigation must be carried out in humans; although in vitro and ex vivo studies are acceptable, the in vivo component must clearly be the more relevant part of the project.

Funding Commitment and Instruments

Starting in 2007, this stand-alone EFSD Programme has committed a total of **Euro 3.8 million** towards clinical research in diabetes, with awards of up to Euro 300,000 over a period of up to three years.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Angelo Avogaro: University of Padova - Italy
Ellen Blaak: Maastricht University - The Netherlands
Rainer Böger: University Medical Centre Hamburg-Eppendorf - Germany
Carmine Fanelli: University of Perugia - Italy
Bettina Nowotny: German Diabetes Center - Düsseldorf, Germany
Allan Vaag: Rigshospitalet – Copenhagen University, Denmark

New Horizons Collaborative Research Initiative

Plan

There is a rich history of diabetes research throughout Europe and its associated states. Historically, however, funding for such research tends to be unevenly distributed. The Foundation now seeks to redress in part this imbalance and to foster inter-regional collaboration in diabetes research throughout Europe by making available grants through the EFSD New Horizons Collaborative Research Initiative

This Programme therefore aims to foster inter-regional collaboration in diabetes research throughout Europe on a competitive basis. It is open to investigators working in institutions in the following countries and proposing to collaborate with an investigator from a European country not on this list: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Hungary, Latvia, Lithuania, FYRo Macedonia, Moldavia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, and Ukraine.

Funding Commitment and Instruments

Up to **Euro 2.1 million** has been made available for the period 2009 - 2011 to fund basic and clinical research grants of up to Euro 100,000 and Euro 300,000 respectively.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Maija Dambrova: Latvian Institute of Organic Synthesis – Latvia *collaborating with*

Rainer Breitling: University of Glasgow - UK

Jan Kopecky: Institute of Physiology - Czech Republic *collaborating with*

Jaap Keijer: Wageningen University - The Netherlands

Koba Kupreishvili: Georgian National Institute of Medical Research - Georgia *collaborating with*

Hans Niessen: Free University Medical Centre - The Netherlands

Adrian Manea: Institute 'Nicolae Simionescu' - Romania *collaborating with*

Shlomo Sasson: Hebrew University of Jerusalem - Israel

Mirjana Pibernik-Okanovic: Vuk Vrhovac University Clinic - Croatia *collaborating with*

Norbert Hermanns: Diabetes Research Institute - Germany

Raivo Uibo: University of Tartu - Estonia *collaborating with*

Bart Roep: Leiden University Medical Center - The Netherlands

Jozef Ukropec: Slovak Academy of Sciences - Slovakia *collaborating with*

Christian Wolfrum: Institute of Molecular Systems Biology - Switzerland

Research Programme in Diabetes and Cancer

Plan

The EFSD Research Programme in Diabetes and Cancer was established in order to stimulate and accelerate European research aimed at investigating why diabetes is associated with increased morbidity and mortality in certain forms of cancer. The role of diabetes therapy including molecular mechanisms is also of interest, and applications for projects carried out in collaboration between diabetes and cancer research institutions are especially welcome.

Funding Commitment and Instruments

Euro 3.7 million has been made available over the next three years for research in the framework of the Programme. Research is supported through the award of grants of up to Euro 100,000 for basic research projects and Euro 400,000 for clinical research projects.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Frédéric Bost: Nice University Hospital - France

Bendix Carstensen: Copenhagen University - Denmark

Craig Currie: Cardiff University - UK *collaborating with*

Edwin Gale: Bristol University – UK

Michelangelo Foti: University of Geneva - Switzerland

Andreas Geier: University Hospital Zurich - Switzerland *collaborating with*

Oliver Tschopp: University Hospital Zurich - Switzerland

Birgit Gustafson: Sahlgrenska University Hospital - Gothenburg, Sweden *collaborating with*

Sahlgrenska University Hospital - Gothenburg, Sweden:

Margit Mahlapuu

Claire Perks: Southmead Hospital - Bristol, UK

Andrew Renehan: University of Manchester - UK *collaborating with*

Iain Buchan: University of Manchester - UK

Guadalupe Sabio Buzo: National Centre for Biotechnology - Madrid, Spain *collaborating with*

Miguel Marcos Martin: University Hospital Salamanca - Spain

Giovanni Solinas: University of Fribourg - Switzerland *collaborating with*

Matthias Wymann: University of Basel – Switzerland

Lonneke van de Poll-Franse: Eindhoven & Tilburg University - The Netherlands *collaborating with* Francois Pouwer: Tilburg University - The Netherlands

EFSD and Amylin

Paul Langerhans Grants on Interaction between the Brain, Gut, Liver and Periphery and its Importance in Diabetes

Background

Amylin Pharmaceuticals Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialisation of innovative medicines. The company was founded in 1987 and since then has built a strong foundation on research and development.

Plan

EFSD and Amylin established a partnership in 2005 to provide grants for studies on the integrated physiology of the entero-insular axis and the brain in metabolic homeostasis, and particularly the following; physiology of release and action of gut hormones including the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulintropic polypeptide (GIP); islet hormones including amylin and glucagon; localisation and expression of GLP-1, GIP, amylin and glucagon receptors and their regulation, impact of hyperglycaemia on expression, release and action of gastrointestinal and pancreatic hormones; cross-talk between gut, brain and islet signals; neural regulation of the gut and islet and the role of central neurohormonal signalling in diabetes and obesity; changes in entero-insular interaction induced by bariatric surgery and neurohormonal regulation of weight loss, including gut, pancreatic and adipocyte-derived hormones.

In 2010, the Programme offered grants up to Euro 100,000 for basic research and Euro 300,000 for clinical research.

Funding Commitments and Instruments

Since its creation in 2005, and with additional funds up to and including 2010, the total funding commitment of the Partnership has reached **Euro 1.6 million**.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Francesca Frigerio: University of Milan - Italy

Viola Nordström: German Cancer Research Center - Heidelberg, Germany

Thomas Solomon: Copenhagen University - Denmark

EFSD and The Chinese Diabetes Society (CDS) and Lilly

Programme for Collaborative Diabetes Research between China and Europe

Background

Founded in 1991, the Chinese Diabetes Society conducts public education programmes, epidemiological surveys and research in China. The mission of CDS is to prevent and treat diabetes and provide information to help educate people living with diabetes, their families, health care professionals, and the public about this disease.

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

Plan

This partnership targets collaborative research endeavours between European and Chinese research centres and/or individual investigators in the area of diabetes and its complications.

Funding Commitment and Instruments

Total funding of **Euro 1.2 million** has been committed from 2008 – 2010. Two basic science research grants in the sum of up to Euro 100,000 and one clinical outcomes research grant in the sum of up to Euro 200,000 will be made available annually, for research to be carried out in China in collaboration with a European research institution.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Haibing Chen: Shanghai Jiaotong University *collaborating with*
Rudolf William Bilous: Newcastle University - UK
Yong Tao: Peking University *collaborating with*
Hans-Peter Hammes: University of Heidelberg - Germany

EFSD and D-Cure

Young Investigator Awards for Collaborative Diabetes Research between Israel and Europe

Background

D-Cure Diabetes Care in Israel R.A. (D-Cure) is a recently established non-profit organisation that aims to advance basic and clinical research into diabetes in Israel. This EFSD/D-Cure Programme is further supported by a charitable donation from another Israeli Foundation and the Berlin Charitable Trust.

Plan

This partnership programme encourages new projects aimed at advancing current knowledge in type 2 diabetes which are undertaken by young investigators working in Israel, in collaboration with an investigator working in another country in Europe.

Funding Commitment and Instruments

Starting in 2009, the partnership has committed a total of **US\$ 350,000** for research grants up to US\$ 75,000 each.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Arie Lev Gruzman: Bar Ilan University *collaborating with*
Jürgen Eckel: German Diabetes Center – Düsseldorf, Germany
Eran Hornstein: Weizmann Institute of Science *collaborating with*
Harry Heimberg: Free University Brussels - Belgium
Rotem Karni: The Hebrew University of Jerusalem *collaborating with*
Per-Olof Berggren: Karolinska Institute – Stockholm, Sweden

EFSD and GlaxoSmithKline

Programme in Immunomodulation and/or Modulation of the Incretin Pathway in Type 1 and Type 2 Diabetes

Background

Headquartered in the UK, and with operations based in the US, GlaxoSmithKline is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. Its mission is to improve the quality of human life by enabling people to do more, feel better and live longer.

Plan

The EFSD/GlaxoSmithKline Grant Programme seeks to promote research that will broaden our understanding of the impact of modulating the immune system in autoimmune type 1 diabetes as well as in inflammation of type 2 diabetes. It also seeks to accelerate research into the role of the incretin pathway in diabetes and its complications and possible interaction or common mechanisms between this pathway and the immune system.

Funding Commitment and Instruments

Established in 2007 and since renewed annually, the total commitment of this partnership to date is **Euro 1.9 million**, made available as grants each of up to Euro 100,000 with special requests for amounts of up to Euro 300,000 in total being considered.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Núria Alonso Pedrol: Hospital Germans Trias - Barcelona, Spain

Victor Gault: University of Ulster - UK

Rosa Simões Fernandes: IBILI - Coimbra, Portugal

Sophie Van Linthout: Charité University Hospital - Berlin, Germany

Sergei Zaitsev : Karolinska Institute - Stockholm, Sweden

**EFSD
and
Juvenile Diabetes Research Foundation
(JDRF)
and
Novo Nordisk**

European Programme in Type 1 Diabetes Research

Background

The mission of the Juvenile Diabetes Research Foundation International (JDRF) is to find a cure for diabetes and its complications through the support of research. JDRF was founded in 1970 by parents of children with diabetes who were convinced that the disease could be cured. JDRF gives more money to diabetes research than any other non-profit, non-governmental health agency in the world.

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Novo Nordisk has companies and information offices in more than 60 countries.

Plan

The EFSD/JDRF/Novo Nordisk Programme in Type 1 Diabetes Research aims to foster multi-disciplinary research targeted at finding a cure for type 1 diabetes and its complications. The specific goals of the Programme are: to promote the highest quality of basic and clinical biomedical research in Europe and its associated countries applicable to type 1 diabetes, to expedite the practical application of scientific advances in our understanding of the aetiology, pathogenesis, treatment and prevention of type 1 diabetes and its complications, to encourage clinical translational research bridging the bench and the bedside, and to increase awareness of type 1 diabetes research throughout Europe.

Funding Commitment and Instruments

The EFSD/JDRF/Novo Nordisk European Programme in Type 1 Diabetes Research was established in 2001 and has to date made a total combined commitment of **Euro 11.75** million.

EFSD/JDRF/Novo Nordisk Programme in Type 1 Diabetes in Europe

Grants of up to Euro 100,000 each were available with special requests for amounts of up to Euro 400,000 in total being considered.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Isabella Artner: Lund University - Sweden

Christian Boitard: Hospital Cochin - Paris, France

Decio L. Eizirik: Free University Brussels - Belgium

Marika Falcone: San Raffaele Scientific Institute - Milan, Italy

Thomas Mandrup-Poulsen: Copenhagen University – Denmark

Rory McCrimmon: Dundee University – UK

Olli Simell: District Hospital of Southwest Finland - Turku, Finland

European Diabetes Research Programme

Background

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

Plan

The EFSD/Lilly European Diabetes Research Programme is established within the frame of the EFSD/Lilly Fund. The goals of the Fund are: to promote increased European research in diabetes, support training and mobility programmes in diabetes research for young clinicians and scientists, and increase awareness of the burden of diabetes and its complications throughout Europe. Launched in 2003, the Fund has now reached a total commitment of **Euro 9.3 million** to fund its various activities, including research grant and fellowship programmes.

Funding Commitment and Instruments

To date, the EFSD/Lilly Fund has contributed **Euro 4.550 million** towards the EFSD/Lilly Diabetes Research Programme, in the form of grants of up to Euro 100,000 each.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Anna Akhmanova: Erasmus Medical Centre - Rotterdam, The Netherlands
Philippe Froguel: Pasteur Institute of Lille - France
Stephan Herzig: German Cancer Research Center - Heidelberg, Germany
Richard Ijzerman: Free University Medical Center - The Netherlands
Sander Kersten: Wageningen University - The Netherlands
Margit Mahlapuu: Gothenburg University - Sweden
Suzanne Mandrup: University of Southern Denmark - Odense, Denmark
Hindrik Mulder: Lund University - Malmö, Sweden
José Ribeiro Bessa: University Pablo de Olavide - Seville, Spain
Roy Taylor: Newcastle University - UK
Emmanuel Van Obberghen: University of Nice – France

EFSD and Merck Sharp & Dohme (MSD)

European Basic Research Programme on Beta Cell Function and Survival

Background

Merck & Co, Inc is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharp & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

Plan

These Programme awards are intended to stimulate and accelerate European research into all aspects of beta cell function and survival, with particular emphasis on the following: increasing beta cell mass/function, mechanisms of glucose-stimulated insulin secretion, mechanisms of beta cell dysfunction, including beta cell gluco- and lipotoxicity, non-invasive imaging of beta cells, and beta cell intermediary metabolism.

Funding Commitment and Instruments

This partnership Programme was established in 2005 and renewed in 2007 for a total commitment of **Euro 3.2 million**, to be distributed in the form of grants, each of up to Euro 100,000.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Nils Billestrup: University of Copenhagen - Denmark
Charna Dibner: University Hospital of Geneva - Switzerland
Jochen Lang: Bordeaux University - Pessac, France
Stephan Schneider: Ruhr-University Bochum - Germany
Anders Tengholm: Uppsala University - Sweden
Bernard Thorens: Lausanne University - Switzerland
Mireille Vasseur-Cognet: Paris Descartes University - France

EFSD and Merck Sharp & Dohme (MSD)

European Clinical Research Programme on Incretins, Gut Physiology and Pancreatic Islets in Type 2 Diabetes

Background

Merck & Co, Inc is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharp & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

Plan

These Programme awards are intended to stimulate and accelerate European research into clinical aspects of type 2 diabetes mellitus, focusing on the following: incretin physiology, DPP-4 inhibition, gut physiology as it relates to metabolic control, and islet cell function and survival. Areas of particular interest include alterations in islet cell mass/function in diabetes and obesity, non-invasive imaging of islet cells, mechanisms of beta cell dysfunction in type 2 diabetes including beta cell gluco- and lipotoxicity, preservation or prevention of further loss of beta cell functional mass in individuals with impaired glucose tolerance and type 2 diabetes, genetic defects that elucidate beta cell dysfunction in type 2 diabetes, mechanisms of glucose dependent insulin and glucagon secretion, incretin regulation of hepatic glucose production, non-glucose actions of incretins, novel gut peptides implicated in metabolism and changes in physiology related to gastric bypass.

Funding Commitment and Instruments

This partnership Programme was established in 2008 for a total commitment of **Euro 2.7 million** to be distributed in the form of grants, each of up to Euro 300,000. In 2009 this amount was increased to Euro 400,000 each.

Awards in 2010

Based on the recommendations of the Review Committee, no awards were made.

EFSD and Novo Nordisk

Partnership for Diabetes Research in Europe

Background

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Headquartered in Denmark, Novo Nordisk has companies and information offices in more than 81 countries.

Plan

This new Programme will accept applications from all fields of diabetes research, including both basic and clinical research.

Funding Commitments and Instruments

This Programme continues the longstanding EFSD/Novo Nordisk Partnership, with a combined total commitment amounting to **Euro 8.8 million**. Grants of up to Euro 100,000 for basic research projects and Euro 400,000 for clinical research projects will be made available each year.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Luc Bouwens: Free University Brussels - Belgium
Per-Ola Carlsson: Uppsala University - Sweden
Malin Flodström-Tullberg: Karolinska Institute - Stockholm, Sweden
Anthony Gavalas: Academy of Athens - Greece
Jarna Hannukainen: Turku University - Finland
Leif Jansson: Uppsala University - Sweden
Josep Jimenez-Chillaron: Sant Joan de Deu Foundation - Barcelona, Spain
Richard Leslie: Queen Mary University of London - UK
Cedric Moro: Rangueil Hospital - Toulouse, France
Tina Vilsbøll: Copenhagen University - Denmark

European Programme for Research into Cardiovascular Risk Reduction in Patients with Diabetes

Background

Pfizer is one of the world's leading healthcare companies, providing human and animal pharmaceuticals, as well as consumer products. As part of its commitment to the care of patients with diabetes, Pfizer is dedicated to supporting research that will help identify ways to reduce cardiovascular risk, further our understanding of optimal treatment options, and ultimately improve the lives of people with diabetes.

Plan

The key objective of this research partnership is to understand better what best impacts cardiovascular risk reduction in patients with diabetes. Research proposals should aim to evaluate the impact of any aspect of the following on CV risk reduction in diabetes: educational tools, programmes and strategies, risk assessment tools/screening and diagnostic procedures and clinical interventions. This Programme replaced the EFSD/Pfizer Resource Awards for European Diabetes Research.

Funding Commitments and Instruments

Since the establishment of this Partnership in 2004, a total of **Euro 1.8 million** has been made available. In the current programme, **Euro 1.2 million** has been allocated to fund research grants up to Euro 300,000 each.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Magnus Jensen: Gentofte University Hospital - Denmark
Claudia Menzaghi: IRCCS - San Giovanni Rotondo, Italy

EFSD and sanofi-aventis

European Research Programme in Micro- and Macrovascular Complications of Diabetes

Background

The sanofi-aventis Group is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas, and produces several medicines to treat diabetes including insulin. Their commitment to diabetes medicine has been longstanding since 1923 and the involvement of Hoechst, a legacy company of sanofi-aventis.

Plan

The key objective of this research partnership is to understand better what best impacts cardiovascular risk reduction in patients with diabetes, aiming to evaluate the impact of any aspect of the following on CV risk reduction in diabetes: educational tools, programmes, strategies, risk assessment tools/screening and diagnostic procedures and clinical interventions.

Funding Commitment and Instruments

A total of **Euro 1.2 million** was committed to fund basic research projects up to Euro 100,000 and clinical research projects up to Euro 400,000. Since its creation in 2006, the EFSD/sanofi-aventis Partnership has made available a total of **Euro 3.625 million**.

Awards in 2010

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Agostino Consoli: University of Chieti - Italy
Hans-Peter Hammes: University of Heidelberg - Germany
Berend Isermann: University of Heidelberg - Germany
Katia Karalis: Academy of Athens - Greece
Ulf Landmesser: University Hospital Zurich - Switzerland
John Pernow: Karolinska Institute - Stockholm, Sweden
Rafael Simó: University Vall d'Hebron - Barcelona, Spain

FELLOWSHIP

PROGRAMMES

2010

Albert Renold Fellowships

Supported by an unrestricted educational grant
from **Merck Sharp & Dohme (MSD)**

Albert Renold Fellowships, each of up to Euro 7,000, enable young scientists to travel to and stay at other institutions in order to learn new techniques in basic or clinical diabetes research. The duration of the stay should not exceed three months.

Albert Renold Fellowships are available throughout the year, and a decision is usually made within three weeks of applying.

In 2010 the following Fellowships were awarded:

Ashok Ayyappa: travelled to Karolinska Institute – Stockholm, Sweden
Noël Barengo: travelled to National University of La Plata – Buenos Aires, Argentina
Huriya Beyan: travelled to University of Miami - USA
Liliane Chamas: travelled to World Health Organisation – Geneva, Switzerland
Maartje de Wit: travelled to Miami University - USA
Teresa Delgado: travelled to University of Pittsburgh - USA
Meri Hovsepian: travelled to Uppsala University - Sweden
Gabriel Loni Ekali: travelled to University of Prague – Czech Republic
Ronald Ma: travelled to Southampton University - UK
Uriëll Malanda: travelled to Oxford University - UK
Laura McCulloch: travelled to University Hospital Leipzig - Germany
Ruth Meex: travelled to Monash University – Clayton, Australia
Bilkisu Mohammed Mubi: travelled to Manchester Royal Infirmary - UK
Mercé Obach Cortadellas: travelled to University of British Columbia – Vancouver, Canada
Stavrola Paschou: travelled to Blizard Institute of Cell and Molecular Science – London, UK
Zalan Péterfi: travelled to Keck School of Medicine – Los Angeles, USA
Maren Pflüger: travelled to VTT Technical Research Centre – Espoo, Finland
Piotr Pietrzak: travelled to Berlin University - Germany
Dorit Schleinitz: travelled to Karolinska Institute – Stockholm, Sweden
Harold Sourij: travelled to University of Oxford - UK
Mary Travers: travelled to Lund University – Malmö, Sweden
Lucia Valentinová: travelled to The Oxford Centre - UK
Nicolas Venteclef: travelled to Karolinska Institute – Stockholm, Sweden
Ulrike Weyer: travelled to Joslin Diabetes Center – Boston, USA
Johannes Mansfeld: travelled to University of Cincinnati – USA
Ines de Sousa Lima: travelled to Harvard Medical School – Boston, USA
Simona Georgiana Popa: travelled to University of Pisa - Italy

EFSD
and
The Chinese Diabetes Society (CDS)
and
Lilly

Research Fellowships

The objective of the EFSD/CDS/Lilly Research Fellowships is to encourage collaborative research in the field of diabetes. Applications for fellowships may be accepted from applicants from China for study in a recognised research institution in Europe or its associated countries. Details of the partner organisations may be found under “EFSD/CDS/Lilly Collaborative Research Programme”.

Two Fellowships of up to Euro 50,000 each are awarded annually. Application may be made by any paid-up member of EASD under the age of 38 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

Total funding of **Euro 300,000** has been committed from 2008 – 2010 for this Fellowship Programme.

In 2010 the following Fellowships were awarded:

Chengjun Sun: Fudan University - Shanghai *collaborating with*

Carani Sanjeevi: Karolinska Institute – Stockholm, Sweden

Mao Dandan: Shu Guang Hospital - Shanghai *collaborating with*

Rory McCrimmon: University of Dundee - UK

EFSD and Lilly

Research Fellowships

The objective of the EFSD/Lilly Research Fellowships is to encourage innovative research in the fields of metabolism and complications of diabetes, and to promote excellence in medical education.

In 2009, the number of Fellowships available was increased from two to four, and this will also be the case in 2010. Each Fellowship Award is up to **Euro 50,000**. Application may be made by any paid-up member of EASD under the age of 38 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

These Fellowships form part of the EFSD/Lilly European Diabetes Research Fund, further details of which may be found under “EFSD/Lilly Diabetes Research Programme”.

In 2010 the following Fellowships were awarded:

Stefan Amisten: University of Oxford - UK
Christian Andersson: Sahlgrenska University – Gothenburg, Sweden
Céline Cruciani-Guglielmacci: University Paris Diderot - France
Heidi de Wet: University of Oxford - UK
Victorine Douin: Rangueil Hospital - Toulouse, France
Gianpaolo Fadini: University of Padova – Italy
Melis Karaca: University of Geneva - Switzerland
Eckhard Lammert: Heinrich-Heine University - Düsseldorf, Germany
Joan-Marc Servitja: IDIBAPS - Barcelona, Spain
Barbara Ukropcova: Slovak Academy of Sciences - Bratislava, Slovakia

**NEW
PROGRAMMES**

2011

EFSD

European Diabetes Research Programme in Patient Education

supported by an educational research grant from
AstraZeneca/BMS

Background

The AstraZeneca/Bristol-Myers Squibb diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treatment of type 2 diabetes.

Plan

This Programme will support research into the clinical and medical evaluation of patient-related outcomes in relation to the type 2 diabetes chronic condition and the benefits of its treatment and management and the potential impact of educational and disease management programmes, focusing on holistic approaches to patients with type 2 diabetes, patient engagement and better understanding of the complex physiological and behavioural aspects of the disease.

Funding Commitment and Instruments

A total of Euro 900,000 for research funding will be distributed over three years from 2011 – 2013 through the award of grants, each of up to Euro 100,000.

Awards in 2011

The deadline for applications is 10 January 2011, with an anticipated award date of April 2011.

EFSD and Janssen

Programme for the Study of the Role of the Kidney in Diabetes

Background

Janssen represents the pharmaceutical companies of Johnson and Johnson, one of the leading healthcare companies in the world. Janssen develops and markets innovative, high-quality pharmaceutical products and services aimed at improving quality of life for people with medical needs across the world, with metabolic diseases as a key area of scientific interest

Plan

This Programme is intended to stimulate and accelerate European research aimed at understanding the role of the kidney in diabetes, with special emphasis on the role of the renal glucose threshold (RGT) as an underlying pathophysiologic mechanism in type 2 diabetes. Both basic and clinical research in this scientific area will be supported.

Funding Commitment and Instruments

A total of Euro 500,000 for research funding will be made available. Research will be supported through the award of grants, each of up to Euro 100,000 for basic research projects and Euro 200,000 for clinical research projects,

Awards in 2011

The deadline for applications is 25 February 2011, with an anticipated award date of May 2011.

EFSD and Merck Sharp & Dohme (MSD)

Fellowships for Research on the Endocrine Pancreas

The objective of the EFSD/MSD Research Fellowships is to encourage innovative research focusing on the endocrine pancreas and to support talented young investigators engaged in diabetes research.

These postdoctoral Fellowships in the amount of Euro 50,000 will be awarded to individuals already holding a PhD, MD or equivalent degree. Application may be made by any paid-up member of EASD under the age of 38 years on 1 January 2011.

EFSD/MSD Fellows are expected to change their place and ideally country of work during the funding period in order to pursue their research project in a new academic environment. However, either the current home or proposed host institution must be based in Europe or an associated country.

Awards in 2011

The deadline for applications is 10 March 2011, with an anticipated award date of June 2011.

Review Committee Members

EFSD is most grateful to the following colleagues who served on the various review committees of the 2010 partnership programmes:

Stephanie Amiel
Angelo Avogaro
Henning Beck-Nielsen
Francesco Beguinot
Christian Berne
Angelika Bierhaus
Nils Billestrup
Jonathon Bodansky
Fatima Bosch
Miriam Cnop
Mark Cooper
Leszek Czupryniak
Stefano Del Prato
Micaela Diamant
Malin Flodström-Tullberg
Paola Fioretto
Allan Flyvbjerg
Ramon Gomis de Barbara
Peter Grant
Hans-Peter Hammes
Torben Hansen
Kristian Hanssen
Steven Kahn
Fredrik Karpe
Filip Knop
Anna Krook
Markku Laakso

Yannick Le Marchand-Brustel
Valeriya Lyssenko
Sten Madsbad
Pierre Maechler
Nils Møller
Claes-Goran Östenson
Arne Östman
Timo Otonkoski
John Petrie
Jacques Philippe
Thomas Pieber
Andrew Renehan
Michael Roden
Guy Rutter
Giorgio Sesti
James Shaw
Michele Solimena
Giatgen Spinas
Coen Stehouwer
Norbert Stefan
Cees Tack
Jean-François Tanti
Jeremy Tavare
Dietholm Tschöpe
Luc Van Gaal
Antonio Vidal-Puig
John Wilding

EFSD

EXECUTIVE COMMITTEE and ADMINISTRATION

Executive Committee:

President:	U Smith - Göteborg
Vice President:	F Bosch - Barcelona
Vice President:	A Boulton - Manchester
Honorary Secretary:	M Stumvoll - Leipzig
Honorary Treasurer:	G Spinass - Zürich
Editor in Chief - <i>Diabetologia</i>:	E Gale - Bristol
Chairman PGESC:	J Nolan - Dublin

Chairman - EFSD: P A Halban - Geneva
Scientific Board: S Amiel – London

F Beguinot - Naples
E Ferrannini - Pisa
J Ferrer - Barcelona
M Laakso – Kuopio
T Pieber - Graz

Executive Director: V Jörgens – Düsseldorf
Vice Director: M Grüsser - Düsseldorf
Co-ordinators: S Köhnen - Düsseldorf
K Sommer - Düsseldorf

The European Foundation for the Study of Diabetes (EFSD)
Rheindorfer Weg 3
40591 Düsseldorf, Germany

Tel: + 49 211 75 84 69-0 Fax: + 49 211 75 84 69-29

www.EuropeanDiabetesFoundation.org

Email: Foundation@easd.org

Bank details

Europäische Stiftung für Diabetesforschung – EFSD
Commerz Bank
Königsallee 37
40300 Düsseldorf, Germany

Account / Konto: 600 2146 00 Code / BLZ: 300 800 00

SWIFT / BIC: DRES DE FF 300

IBAN: DE31 3008 0000 0600 2146 00

EFSD is registered as a non-profit Foundation in Düsseldorf, Germany under registration number: 15.2.1-St.767
and at the Inland Revenue in Düsseldorf, Germany under tax number: 106/5744/1547